Improving screening for resistant bacteria in hospital patients
Part of Infections clinical trials.
This study looks at a faster test to find CPE, a type of bacteria that is resistant to many antibiotics. If you test positive for CPE while in the hospital, your information may be used to help improve how we screen and manage this bacteria.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years of age or older.
- You are a medical patient currently admitted to the acute medical unit.
- You have already had a routine rectal screening test for CPE (a type of bacteria that is resistant to many antibiotics).
- Your CPE test result is positive, meaning the bacteria was found.
- You are willing to have a rectal swab test, and it is safe for you to have one.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study checks if a special test (Xpert Carba-R) can find a type of drug-resistant bacteria, called CRE, in fluid from the lungs and in rectal swabs. It might help doctors treat lower respiratory tract infections more effectively.
This study looks at whether a rapid test can help doctors detect CPE bacteria (which are resistant to many antibiotics) sooner, and whether using infection control measures can stop these bacteria from spreading. It may help you get the right care and reduce the risk of infection while in the hospital.
This study looks at whether a simple rectal swab test can help predict the risk of developing infections that are resistant to common antibiotics. It focuses on patients in the intensive care unit (ICU) who have already had this swab done as part of their care.
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
This study looks at how well a new antibiotic (cefiderocol) works against a tough type of Klebsiella pneumoniae bacteria that is resistant to many other antibiotics. It may help find better treatments for serious infections.
This trial studies whether cefiderocol plus ampicillin-sulbactam works better than colistin (sometimes with meropenem) for serious infections caused by carbapenem-resistant Acinetobacter baumannii (a hard-to-treat germ). It may help by finding a more effective antibiotic plan for people with these severe hospital-acquired infections.
Hear when a new Carbapenem-Resistant Enterobacteriaceae trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.